A citation-based method for searching scientific literature

I F Faneyte, J G Schrama, J L Peterse, P L Remijnse, S Rodenhuis, M J van de Vijver. Br J Cancer 2003
Times Cited: 221







List of co-cited articles
508 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
18



Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
17

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, T L Smith, F C Ames, K K Hunt, K Dhingra, R L Theriault, G Singh, S M Binkley, N Sneige,[...]. J Clin Oncol 1999
16

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
16

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste Gentilini, Paolo Veronesi, Richard D Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini,[...]. Clin Cancer Res 2004
263
16

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, W Fraser Symmans, Nuhad Ibrahim, Massimo Cristofanilli, Keith Anderson, Kenneth R Hess, James Stec, Mark Ayers, Peter Wagner,[...]. Clin Cancer Res 2005
15

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
15

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Valentina Guarneri, Kristine Broglio, Shu-Wan Kau, Massimo Cristofanilli, Aman U Buzdar, Vicente Valero, Thomas Buchholz, Funda Meric, Lavinia Middleton, Gabriel N Hortobagyi,[...]. J Clin Oncol 2006
436
15

Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett. J Clin Oncol 2005
576
15

Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, Peter M Ravdin, Malcolm M Hayes, Karen A Gelmon. Lancet Oncol 2010
747
15

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
913
14

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
14

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
R J Burcombe, A Makris, P I Richman, F M Daley, S Noble, M Pittam, D Wright, S A Allen, J Dove, G D Wilson. Br J Cancer 2005
129
14


Changes in tumour biological markers during primary systemic chemotherapy (PST).
Hans Neubauer, Christian Gall, Ulrich Vogel, Rene Hornung, Diethelm Wallwiener, Erich Solomayer, Tanja Fehm. Anticancer Res 2008
55
23

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
Robin L Jones, Janine Salter, Roger A'Hern, Ash Nerurkar, Marina Parton, Jorge S Reis-Filho, Ian E Smith, Mitchell Dowsett. Breast Cancer Res Treat 2009
199
12

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
S van de Ven, V T H B M Smit, T J A Dekker, J W R Nortier, J R Kroep. Cancer Treat Rev 2011
146
12

The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Amy L Adams, Isam Eltoum, Helen Krontiras, Wenquan Wang, David C Chhieng. Breast J 2008
49
24


Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, Roger A'Hern, John Bartlett, R Charles Coombes, Jack Cuzick, Matthew Ellis, N Lynn Henry, Judith C Hugh, Tracy Lively,[...]. J Natl Cancer Inst 2011
12

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
820
11

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
11

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies, Philip S Bernard, Joel S Parker,[...]. J Natl Cancer Inst 2009
11

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, J P Julien, M Tubiana-Hulin, C Vandervelden, L Duchateau. J Clin Oncol 2001
754
10

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
10

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
10

Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.
Zsuzsanna Varga, Rosmarie Caduff, Bernhard Pestalozzi. Virchows Arch 2005
39
25

Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
Masako Kasami, Takayoshi Uematsu, Masatake Honda, Tsugumi Yabuzaki, Junichi Sanuki, Yoshihiro Uchida, Haruhiko Sugimura. Breast 2008
57
17


Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Peter A Fasching, Katharina Heusinger, Lothar Haeberle, Melitta Niklos, Alexander Hein, Christian M Bayer, Claudia Rauh, Ruediger Schulz-Wendtland, Mayada R Bani, Michael Schrauder,[...]. BMC Cancer 2011
218
10

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, G de Castro, M Colozza, M S Mano, V Durbecq, C Sotiriou, D Larsimont, M J Piccart-Gebhart, M Paesmans. Br J Cancer 2007
616
10

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, Deborah Francis, Daniel J Booser, Eva S Thomas, Richard L Theriault, Lajos Pusztai, Marjorie C Green, Banu K Arun, Sharon H Giordano,[...]. J Clin Oncol 2005
832
9

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
672
9

Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.
S Taucher, M Rudas, M Gnant, K Thomanek, P Dubsky, S Roka, T Bachleitner, D Kandioler, C Wenzel, G Steger,[...]. Endocr Relat Cancer 2003
56
16

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003
549
9



Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Michael Untch, Mahdi Rezai, Sibylle Loibl, Peter A Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, Jörn Hilfrich, Holger Eidtmann, Bernd Gerber,[...]. J Clin Oncol 2010
375
8

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
8

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
783
8


Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, Mitsuhiro Hayashi, Nobuyuki Arima. Breast Cancer 2010
97
8

The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer.
Susan H Lee, Maureen A Chung, M Ruhul Quddus, Margaret M Steinhoff, Blake Cady. Am J Surg 2003
44
18

Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy--implications for a pathologist.
Tanuja Shet, Atin Agrawal, Roshni Chinoy, Rohini Havaldar, Vani Parmar, Rajan Badwe. Breast J 2007
29
27

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Elizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, Funda Meric-Bernstam, Kelly K Hunt, Shaheenah Dawood, Francisco J Esteva, Aman U Buzdar, Huiqin Chen, Sameena Eksambi,[...]. Clin Cancer Res 2009
222
8

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
J Chang, M Ormerod, T J Powles, D C Allred, S E Ashley, M Dowsett. Cancer 2000
141
8


Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.
Ho-Chang Lee, Hyoungsuk Ko, Hyesil Seol, Dong-Young Noh, Wonshik Han, Tae-You Kim, Seock-Ah Im, In Ae Park. J Breast Cancer 2013
24
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.